Bioavailability of Tc-99m-paclitaxel-glucuronide (Tc-99m-PAC-G)

An antitumor agent paclitaxel (PAC) has been proved to be efficient in the treatment of breast and ovarian cancer. Glucuronic acid-derived paclitaxel compound (paclitaxel-glucuronide (PAC-G)) was enzymatically synthesized using microsome preparate separated from rat livers. The biodistribution mechanism of PAC-G in healthy female Albino Wistar rats has been investigated. The expected structure is confirmed according to LC/MS results, and the possible attachment is to C2-hydroxyl group. PAC-G was labeled with Tc-99m and the radiochemical yield of radiolabeled compound (Tc-99m-PAC-G) was 98.00 +/- 2.74% (n = 9). The range of the breast/blood and breast/muscle ratios is approximately between 3 and 35 in 240 min. All these experimental studies indicate that Tc-99m-PAC-G may potentially be used in breast tissue as an imaging agent.